Skip to main content
News

Australian Nuclear Science and Technology Organization (ANSTO), the new production partner of OncoBeta® GmbH in Australia

Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia

Tuesday 13th July, 2021

Garching n. Munich, Germany and Lucas Heights, NSW, Australia – OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies is pleased to announce that it has formalized it’s manufacturing partnership with the Australian Nuclear Science and Technology Organization (ANSTO).

Following the completion of all regulatory approvals ANSTO will produce OncoBeta’s novel Rhenium-SCT® therapeutic for the treatment of non-melanoma skin cancer. OncoBeta® GmbH expects to launch Rhenium-SCT® by late 2021.

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. It is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. OncoBeta’s Rhenium-SCT® will offer a new and highly effective treatment option to address this large Australian medical burden. 

Nicholas H. Vetter, Chief Operating Officer at OncoBeta® GmbH and CEO of OncoBeta International GmbH stated: “This is a huge step forwards for our organization. We are very excited to bring our technology to Australia and ANSTO is a key partner of ours in the goal of helping thousands of Australians afflicted with non-melanoma skin cancer.”

Mar Olmeda Palomar, Medical Engineering Manager at OncoBeta® GmbH stated: “After the successful commissioning of the production line at ANSTO, we are more confident than ever in our partnership with them. It’s been a pleasure to work closely with ANSTO‘s experienced and motivated team. We believe they are the best partner to help us bring the Rhenium-SCT® to Australia.”

ANSTO General Manager Business Development and Commercialization, Rosanne Robinson stated, “ANSTO has a long-standing relationship with OncoBeta® GmbH and is excited to be their Australian manufacturing partner. Commissioning of the production line has been completed and we look forward to Australian patients having access to OncoBeta’s innovative therapy for non-melanoma skin cancers. ANSTO has extensive experience in the manufacturing and delivering radiopharmaceutical diagnostics, therapies and medical devices and this project enables us to continue delivering on our core mission of improving the health of Australians and supporting industry. OncoBeta® GmbH joins our growing nandin innovation community, focussed on attracting entrepreneurs, early stage start-ups and innovative companies who want to leverage the opportunity to be co-located with ANSTO and to access our unique expertise in the nuclear industry.” 

Back